Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Protez Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

The menace of drug resistant bacteria continues to grow. As Big Pharma has exited early-stage antibacterial R&D in recent years, start-ups like Protez Pharmaceuticals have filled the void.

You may also be interested in...

Lux Biosciences Inc.

Ophthalmology-focused Lux Biosciences Inc. joins the ranks of recently founded in-licensers that have pulled down massive A-rounds on the back of management's track record and an in-licensed prospect. Lux's lead candidate is a calcineurin inhibitor; its initial target is uveitis.

TRACON Pharmaceuticals Inc.

TRACON Pharmaceuticals approach to targeted cancer therapeutics involves creating monoclonal antibodies that home in on cellular receptors that are unique to cancer cells, as well as delivery systems that target cancer tissue, in the hope of destroying cancer cells but leaving healthy tissue. Founded in early 2005, the company already has two promising in-licensed compounds in development.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts